Synthesis and screening of bicyclic carbohydrate-based compounds: A novel type of antivirals

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 6, 2006, Pages 1495-1498

  Van Hoof, Steven ^a   Ruttens, Bart ^a   Hubrecht, Idzi ^a   Smans, Gert ^a   Blom, Petra ^a   Sas, Benedikt ^b   Van Hemel, Johan ^b   Vandenkerckhove, Jan ^b   Van Der Eycken, Johan ^a  

^a GHENT UNIVERSITY   (Belgium)

^b Kemin Industries Inc   (United States)

Author keywords

Anti CMV; Antiviral; Carbohydrates; Cytomegalovirus

Indexed keywords

ANTIVIRUS AGENT; BICYCLIC CARBOHYDRATE; CARBOHYDRATE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; BICYCLO COMPOUNDS; CARBOHYDRATES; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; LUNG; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 32044446701     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.12.048     Document Type: Article

References (20)

1. F. Tropper, and M. Bednarski S.M. Hecht Bioorganic Chemistry: Carbohydrates 1999 Oxford University Press, Inc. New York 335 369
2. R.L. Schnaar Adv. Pharmacol. 23 1992 35
3. J.H. Musser Annu. Rep. Med. Chem. 27 1992 301
4. Sas, B.; Van der Eycken, J.; Van hemel, J.; Blom, P.; Vandenkerckhove, J.; Ruttens, B. PCT Int. Appl. WO2003032905, 2003.
5. P. Blom, B. Ruttens, S. Van Hoof, I. Hubrecht, J. Van der Eycken, B. Sas, J. Van hemel, and J. Vandenkerckhove J. Org. Chem. 70 2005 10109
6. S. Landolfo, M. Gariglio, G. Gribaudo, and D. Lembo Pharmacol. Therapeut. 98 2003 269
7. C.S. Crumpacker N. Engl. J. Med. 335 1996 721
8. R. Snoeck, T. Sakuma, and E. De Clercq Antimicrob. Agents Chemother. 32 1991 1839
9. L. Gérard, and D. Salmon-Céron Int. J. Antimicrob. Ag. 5 1995 209
10. R.F. Azad, V. Brown-Driver, R.W. Buckheit, and K.P. Anderson Antivir. Res. 28 1995 101
11. S. Sánchez Puch, C. Ochoa, G. Carballal, C. Zala, P. Cahn, R. Brunet, H. Salomón, and C. Videla J. Clin. Virol. 30 2004 271
12. W.W. Ogilvie Curr. Med. Chem. - Anti-Infect. Agents 1 2002 177
13. E. De Clercq Mini-Rev. Med. Chem. 2 2002 163
14. E. De Clercq J. Antimicrob. Chemoth. 51 2003 1079
15. M.J. Panigot, K.A. Humphries, and R.W. Curley Jr. J. Carbohydr. Chem. 13 1994 303
16. M.J. Panigot, and R.W. Curley Jr. J. Carbohydr. Chem. 13 1994 293
17. M. Mizuno, M. Kanai, A. Iida, and K. Tomioka Tetrahedron 53 1997 10699
18. J. Thiem, V. Duckstein, A. Prahst, and M. Matzke Liebigs Ann. Chem. 1987 289
19. 50) was defined as the compound concentration required to reduce the cell growth by 50%. During the antiviral assay, the minimum cytotoxic concentration (MCC) was evaluated at day 7 as the lowest compound concentration giving microscopically visible cytotoxicity on the confluent cells. J. Neyts, G. Andrei, R. Snoeck, A. Meerbach, and E. De Clercq J. Sinclair Cytomegalovirus Protocols 2000 Humana Press Totowa, NJ 129 152
20. 3).